

Media Contacts:

Caren Browning
King + Company
00 1 212 561-7464
Caren.Browning@kingcompr.com

Semmy Rülf
Chairman of the Board
+46 (0)709 312730
semmy.rulf@dignitana.se

DIGNITANA CONTINUES AUGMENTED GROWTH ACROSS THE U.S.

Scalp Cooling Technology for Women with Breast Cancer Available at 71 Medical Centers

Lund, Sweden – May 23, 2017—Dignitana AB, an international leader in medical scalp-cooling technology and the manufacturer of the DigniCap® scalp cooling system, announced today the availability of the DigniCap® system in seven additional sites across the U.S.

The DigniCap® Scalp Cooling System was the first scalp cooling device to complete rigorous FDA clinical trials and receive FDA clearance for use by women with breast cancer undergoing chemotherapy. In the pivotal trial seven out of ten patients with early-stage breast cancer kept at least 50% of their hair. Results from Dignitana's multi-center clinical trial were recently published in the prestigious [Journal of the American Medical Association](#) (JAMA).

These seven new sites make DigniCap® accessible at a total of 71 U.S. medical centers across 20 states. The following cancer treatment centers are the most recent U.S. sites to include the DigniCap® scalp cooling system as part of their breast cancer treatment and care regimens:

- [Mayo Clinic](#)
Phoenix, Arizona
- [Michael Benjamin](#)
West Hills, California
- [Moffitt Cancer Center at International Plaza](#)
Tampa, Florida
- [NYU Langone Perlmutter Cancer Center](#)
New York, New York
- [Pinellas Hematology Oncology](#)
St. Petersburg, Florida
- [South Carolina Oncology Associates](#)
Columbia, South Carolina
- [Wellness Oncology](#)
West Hills, California

"We are inspired by the feedback we have received from medical centers across the U.S. and the demand for this revolutionary scalp cooling treatment," said William Cronin, Chief Executive Officer of Dignitana, Inc., the U.S. subsidiary of Dignitana AB. "We continue to be humbled and honored to work with so many patient-focused medical centers to make the DigniCap® scalp cooling system easily accessible to breast cancer patients undergoing chemotherapy and offer this extraordinary treatment option on a whole new scale."

The device features a patented tight-fitting silicone cooling cap that is placed directly on the head, and an outer neoprene cap that insulates and secures the silicone cap. The cooling cap is connected to a cooling and control unit with touch screen prompts. A liquid coolant circulates throughout the silicone cap, delivering consistent and controlled cooling to all areas of the scalp. The cap is fitted to the head, and the temperature of the scalp is lowered, resulting in vasoconstriction with reduced delivery of chemotherapy to the scalp, as well as reduced cellular uptake of drugs due to decreased intra follicular metabolic rate. These factors together reduce the risk of chemotherapy-induced hair loss.

This information is information that Dignitana AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, by the above contact, for publication at 14,30 (CET), May 23, 2017.

About Dignitana AB (publ)

Dignitana is a Swedish public company based in Lund and manufacturer of the medical cooling device DigniCap®. Dignitana AB is listed on Nasdaq First North Stockholm and has appointed Erik Penser Bank as Certified Adviser. For more information visit www.dignitana.com

About The DigniCap® Scalp Cooling System

Dignitana's core product, DigniCap®, is a patented scalp-cooling system that offers cancer patients the ability to keep their hair during chemotherapy. DigniCap® provides continuous cooling with high efficacy, safety and acceptable patient comfort.

###